Treatment of chronic viral hepatitis C with direct acting antiviral agent: review
- Authors: Malov VA1, Ubeeva EA2, Ubeeva IP2, Nikolaev SM2, Umbetova KT1
-
Affiliations:
- Sechenov First Moscow State Medical University
- Dorgi Banzarov Buryat State University
- Issue: Vol 91, No 11 (2019)
- Pages: 86-89
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33713
- DOI: https://doi.org/10.26442/00403660.2019.11.000307
- ID: 33713
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
V A Malov
Sechenov First Moscow State Medical Universityд.м.н., проф., проф. каф. инфекционных болезней МПФ ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет), ORCID: 0000-0002-6157-1654 Moscow, Russia
E A Ubeeva
Dorgi Banzarov Buryat State Universityаспирант каф. фармакологии ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова»; ORCID: 0000-0002-9835-2279 Ulan-Ude, Russia
I P Ubeeva
Dorgi Banzarov Buryat State Universityд.м.н., проф., проф. каф. инфекционных болезней ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова», ORCID: 0000-0001-8206-8436 Ulan-Ude, Russia
S M Nikolaev
Dorgi Banzarov Buryat State Universityд.м.н., проф., проф. каф. фармакологии ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова», ORCID: 0000-0002-5833-7576 Ulan-Ude, Russia
K T Umbetova
Sechenov First Moscow State Medical Universityд.м.н., проф. каф. инфекционных болезней МПФ ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет), ORCID: 0000-0002-0902-9267 Moscow, Russia
References
- Климова Е.А. Гепатит С. В кн.: Инфекционные болезни: национальное руководство. Под ред. Ющука Н.Д., Венгерова Ю.Я. М.: ГЭОТАР-Медиа, 2018:688-702.
- Пименов Н.Н., Комарова С.В., Карандашова И.В., Цапкова Н.А., Волчкова Е.В., Чуланов В.П. Гепатит C и его исходы в России: анализ заболеваемости, распространенности и смертности до начала программы элиминации инфекции. Инфекционные болезни. 2018;16(3):37-45. doi: 10.20953/1729-2018-3-37-45
- Kwo P.Y, Poordad F, Asatryan A, Wang S, Wyles D.L, Hassanein T, Felizarta F, Sulkowski M.S, Gane E, Maliakkal B, Overcash J.S, Gordon S.C, Muir A.J, Aguilar H, Agarwal K, Dore G.J, Lin C.W, Liu R, Lovell S.S, Ng T.I, Kort J, Mensa F.J. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263-71. doi: 10.1016/j.jh ep.2017.03.039
- Baatarkhuu O, Kim D.Y, Ahn S.H, Nymadawa P, Dahgwahdorj Y, Shagdarsuren M, Park J.Y, Choi J.W, Oyunbileg J, Oyunsuren T, Han K.H. Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population - based nationwide study. Liver Int. 2008;28(10):1389-95. doi: 10.1111/j.1478-3231.2008.01820.x
- Qureshi H, Bile K.M, Jooma R, Alam S.E, Afridi H.U. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J. 2010;16(Suppl):S15-S23.
- Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-S57. doi: 10.1016/j.jhep.2014.07.027
- Spradling P.R, Rupp L, Moorman A.C, Lu M, Teshale E.H, Gordon S.C, Nakasato C, Boscarino J.A, Henkle E.M, Nerenz D.R, Denniston M.M, Holmberg S.D; Chronic Hepatitis Cohort Study Investigators. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55(8):1047-55. doi: 10.1093/cid/cis616
- Manns M.P, Buti M, Gane E, Pawlotsky J.M, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. doi: 10.1038/ nrdp.2017.6
- European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-36. doi: 10.1016/S2468-1253(17)30045-6
- Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41. doi: 10.3748/wjg.v13.i17.2436
- Рекомендации по диагностике и лечению взрослых больных гепатитом С. Ющук Н.Д. и др. М.:ГЭОТАР-Медиа, 2017.
- Stanaway J.D, Flaxman A.D, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad L.J, Assadi R, Bhala N, Cowie B, Forouzanfour M.H, Groeger J, Hanafiah K.M, Jacobsen K.H, James S.L, Mac Lachlan J, Malekzadeh R, Martin N.K, Mokdad A.A, Mokdad A.H, Murray C.J.L, Plass D, Rana S, Rein D.B, Richardus J.H, Sanabria J, Saylan M, Shahraz S, So S, Vlassov V.V, Weiderpass E, Wiersma S.T, Younis M, Yu C, E.l Sayed Zaki M, Cooke G.S. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-8. doi: 10.1016/ S0140-6736(16)30579-7
- Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon S.C, Schultz M, Davis M.N, Kayali Z, Reddy K.R, Jacobson I.M, Kowdley K.V, Nyberg L, Subramanian G.M, Hyland R.H, Arterburn S, Jiang D, McNally J, Brainard D, Symonds W.T, McHutchison J.G, Sheikh A.M, Younossi Z, Gane E.J. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87. doi: 10.1056/NEJMoa1214853
- Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. doi: 10.1016/S2468-1253(16)30181-9
- Reau N, Kwo P.Y, Rhee S, Brown R.S. Jr, Agarwal K, Angus P, Gane E, Kao J.H, Mantry P.S, Mutimer D, Reddy K.R, Tran T.T, Hu Y.B, Gulati A, Krishnan P, Dumas E.O, Porcalla A, Shulman N.S, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68(4):1298-307. doi: 10.1002/ hep.30046
- Scheel T.K, Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine. 2013;19(7):837-49. doi: 10.1038/nm.3248
- Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285(5424):110-3.
- Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette J.C, Opolon P. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum. 1999;42(10): 2204-12.
- Thein H.H, Yi Q, Dore G.J, Krahn M.D. Estimation of stage - specific fibrosis progression rates in chronic hepatitis C virus infection: a meta - analysis and meta - regression. Hepatology. 2008;48(2):418-31. doi: 10.1002/hep.22375
- Takehara T, Hayashi N, Mita E, Hagiwara H, Ueda K, Katayama K, Kasahara A, Fusamoto H, Kamada T. Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implications for hepatitis C virus replication in infected tissue. Hepatology. 1992;15(3):387-90.
- Revie D, Salahuddin S.Z. Human cell types important for Hepatitis C Virus replication in vivo and in vitro: old assertions and current evidence. Virol J. 2011;8:346. doi: 10.1186/1743-422X-8-346
- Everson G.T, Towner W.J, Davis M.N, Wyles D.L, Nahass R.G, Thuluvath P.J, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, Mc Nally J, Brainard D.M, Han L, Doehle B, Mc Hutchison J.G, Morgan T, Chung R.T, Tran T.T. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015;163(11):818-26. doi: 10.7326/M15-1000
- Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects. https://clinicaltrials.gov/ct2/show/ NCT03092375
- Owens C.M, Brasher B.B, Polemeropoulos A, Rhodin M.H, Mc Allister N, Wong K.A, Jones C.T, Jiang L, Lin K, Or Y.S. Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor. Antimicrob Agents Chemother. 2016;60(10):6216-26. doi: 10.1128/AAC.00815-16
- Forns X, Lee S.S, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson D.R, Yu Y, Krishnan P, Lin C.W, Kort J.J, Mensa F.J. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single - arm, open - label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062-8. doi: 10.1016/ S1473-3099(17)30496-6
- Zeuzem S, Foster G.R, Wang S, Asatryan A, Gane E, Feld J.J, Asselah T, Bourlière M, Ruane P.J, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang W.L, Stedman C.A, Flamm S, Kwo P, Dore G.J, Sepulveda-Arzola G, Roberts S.K, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas H.E, Bruck R, Fuster F, Paik S.W, Felizarta F, Kort J, Fu B, Liu R, Ng T.I, Pilot-Matias T, Lin C.W, Trinh R, Mensa F.J. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354-69. doi: 10.1056/ NEJMoa1702417
- Kwo P.Y, Poordad F, Asatryan A, Wang S, Wyles D.L, Hassanein T, Felizarta F, Sulkowski M.S, Gane E, Maliakkal B, Overcash J.S, Gordon S.C, Muir A.J, Aguilar H, Agarwal K, Dore G.J, Lin C.W, Liu R, Lovell S.S, Ng T.I, Kort J, Mensa F.J. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263-71. doi: 10.1016/j.jhep.2017.03.039
- Wilson E, et al. Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience (RESOLVE). https://clinicaltrials.gov/ct2/show/NCT02745535
- Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri M.I, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. Chronic hepatitis C: This and the new era of treatment. World J Hepatol. 2016;8(2):92-106. doi: 10.4254/wjh.v8.i2.92
- Foster G.R, Afdhal N, Roberts S.K, Bräu N, Gane E.J, Pianko S, Lawitz E, Thompson A, Shiffman M.L, Cooper C, Towner W.J, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman C.A, Mo H, Dvory-Sobol H, Han L, Wang J, Mc Nally J, Osinusi A, Brainard D.M, Mc Hutchison J.G, Mazzotta F, Tran T.T, Gordon S.C, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608-17. doi: 10.1056/NEJMoa1512612
- Manns M.P, Cornberg M. Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis. 2013;13(5):378-9. doi: 10.1016/S1473-3099(13)70074-4
- Feld J.J, Jacobson I.M, Hézode C, Asselah T, Ruane P.J, Gruener N, Abergel A, Mangia A, Lai C.L, Chan H.L, Mazzotta F, Moreno C, Yoshida E, Shafran S.D, Towner W.J, Tran T.T, Mc Nally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard D.M, Mc Hutchison J.G, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599-607. doi: 10.1056/NEJMoa 1512610
- El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol. 2016; 9(11):1413-21. doi: 10.1080/17512433.2016.1233813
- Asselah T, Kowdley K.V, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry P.S, Hezode C, Marinho R.T, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng T.I, Krishnan P, Lin C.W, Mensa F.J. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417-26. doi: 10.101 6/j.cgh.2017.09.027
- Kliemann D.A, Tovo C.V, da Veiga A.B, de Mattos A.A, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol. 2016;22(40):8910-7. doi: 10.3748/wjg.v22.i40.8910
- Апросина З.Г. Хронический активный гепатит как системное заболевание. М.: Медицина, 1981.
- Chung R.T, et al. Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant. https://clinicaltrials.gov/ct2/show/ NCT03623568
- Cacoub P, Commarmond C, Sadoun D, Desbois A.C. Hepatitis C virus infection and rheumatic diseases: the impact of direct - acting antiviral agents. Rheum Dis Clin North Am. 2017;43(1):123-32. doi: 10.1016/j.rdc.2016.09.011
- Negro F, Forton D, Craxi A, Sulkowski M.S, Feld J.J, Manns M.P. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345-60. doi: 10.1053/j.gastro.2015.08.035
![](/img/style/loading.gif)